Knee Hyaluronic Acid Injections Market to Reach USD 4.16 Billion by 2036, Forecasts Future Market Insights

The global knee hyaluronic acid injections market is projected to increase from USD 2,410.2 million in 2026 to USD 4,156.1 million by 2036, registering a compound annual growth rate (CAGR) of 5.6% over the forecast period, according to Future Market Insights (FMI). Market demand is supported by the continued use of viscosupplementation in knee osteoarthritis management, established outpatient treatment pathways, and interest in non-surgical approaches to managing joint symptoms.

Knee hyaluronic acid injections are administered into the joint to supplement synovial fluid and support symptom management in selected patients. Demand is shaped by treatment preferences, physician assessment, dosing schedules, and access to orthopedic services. FMI identifies knee osteoarthritis as the leading indication and three-injection regimens as the largest product segment in 2026.

👉 Get Detailed Market Forecasts, Competitive Benchmarking, and Pricing Trends: https://www.futuremarketinsights.com/reports/sample/rep-gb-1099

Key Market Highlights

· Market size in 2026: USD 2,410.2 million

· Projected market size by 2036: USD 4,156.1 million

· Forecast CAGR (2026-2036): 5.6%

· Leading indication: Knee osteoarthritis, accounting for 92.0% of the market in 2026

· Leading product segment: Three-injection regimens, projected to account for 47.8% of product demand in 2026

· Leading end-user categories: Ambulatory surgical centers and orthopedic clinics

· Fastest-growing country highlighted by FMI: China, with a projected CAGR of 8.9%

What Is Driving Demand for Knee Hyaluronic Acid Injections?

The rising need to manage knee osteoarthritis is a central factor shaping market expansion. Patients and healthcare providers continue to consider a range of treatment options before escalating to surgical interventions. Hyaluronic acid injections form part of this treatment landscape, although their suitability and effectiveness vary by patient, clinical circumstances, and treatment guidelines.

Outpatient orthopedic services also influence demand. Ambulatory surgical centers and specialist clinics provide settings for injection-based treatments and follow-up care. Repeat treatment cycles may contribute to ongoing product utilization, while dosing convenience and the number of clinic visits required remain important considerations for providers and patients.

Product differentiation is another market factor. Manufacturers are competing through formulation characteristics, dosing schedules, clinical evidence, and physician familiarity. Single-injection formats may appeal where fewer visits are preferred, while multi-injection regimens continue to have a role in established clinical practices.

Country-Level Growth Outlook

FMI forecasts varying growth rates across major national markets between 2026 and 2036:

· China: 8.9% CAGR, supported by expanding orthopedic care access and growing demand for osteoarthritis management.

· Japan: 8.2% CAGR, with demographic trends and mobility-preservation needs contributing to demand.

· India: 7.8% CAGR, supported by increasing access to orthopedic services and outpatient treatment options.

· United Kingdom: 5.5% CAGR, reflecting continued use within selected non-surgical treatment pathways.

· Germany: 4.0% CAGR, with demand influenced by clinical evidence, product quality, and established orthopedic services.

· United States: 3.8% CAGR, supported by established orthopedic infrastructure and continued use of viscosupplementation in selected patient groups.

These forecasts indicate opportunities across both established and emerging healthcare markets. However, adoption will continue to depend on clinical practice, treatment recommendations, affordability, reimbursement arrangements, and patient selection.

Competitive Landscape and Industry Developments

According to FMI, competition in the knee hyaluronic acid injections market increasingly centers on dosing convenience, formulation innovation, clinical evidence, and access to orthopedic care channels.

Key companies profiled in the report include Sanofi S.A., Bioventus LLC, Ferring B.V., Zimmer Biomet, Seikagaku Corporation, Fidia Farmaceutici S.p.A., Anika Therapeutics, Inc., LG Chem, OrthogenRx, Hanmi Pharm Co., Ltd., and Chugai Pharmaceutical Co., Ltd.

Manufacturers are seeking to differentiate their offerings through single- and multi-injection products and formulation development. Combination approaches are also being explored within the broader product landscape, although clinical suitability and regulatory requirements remain important considerations for adoption.

FMI Analyst Perspective

Sabyasachi Ghosh, Associate Vice President at Future Market Insights, notes that dosing convenience, clinical evidence, and outpatient workflow efficiency are increasingly influencing product selection. Suppliers that address physician needs while supporting clear dosing options and credible clinical data may be better positioned as providers evaluate treatment choices for osteoarthritis management.

Outlook Through 2036

The knee hyaluronic acid injections market is expected to expand steadily through 2036 as osteoarthritis management remains an important component of orthopedic care. Growth opportunities will vary by country and product category, with China, Japan, and India forecast to outpace several mature markets.

For manufacturers, continued investment in product differentiation, clinical evidence, and healthcare-provider engagement may help strengthen market positioning. At the same time, treatment decisions will remain dependent on individual clinical assessment and applicable medical guidance.

Access Full Report: https://www.futuremarketinsights.com/reports/knee-hyaluronic-acid-injections-market

Frequently Asked Questions

1. What is the projected size of the knee hyaluronic acid injections market by 2036?

FMI projects the market to reach USD 4,156.1 million by 2036.

2. What is the market's forecast CAGR?

The market is forecast to grow at a CAGR of 5.6% between 2026 and 2036.

3. Which indication dominates the market?

Knee osteoarthritis is the leading indication, accounting for a projected 92.0% share in 2026.

4. Which country is expected to grow fastest?

China is forecast to register the highest growth among the highlighted countries, at a CAGR of 8.9% from 2026 to 2036.

5. Who are the key companies profiled?

Major companies include Sanofi, Bioventus, Ferring, Zimmer Biomet, Seikagaku Corporation, Fidia Farmaceutici, Anika Therapeutics, LG Chem, OrthogenRx, Hanmi Pharm, and Chugai Pharmaceutical.

Rahul Singh
AVP - Marketing and Growth Strategy
Future Market Insights, Inc.
+91 8600020075
For Sales - sales@futuremarketinsights.com
For Media - Rahul.singh@futuremarketinsights.com
For Web - https://www.futuremarketinsights.com

Future Market Insights (FMI) is a global market intelligence and consulting firm providing comprehensive market research, competitive intelligence, and strategic business insights across industries. The firm delivers detailed forecasts, technology analysis, and data-driven recommendations that support informed decision-making for manufacturers, investors, distributors, and policymakers worldwide.

This release was published on openPR.